Therapy News and Research

RSS

CNS Response to present results from depression efficacy study at U.S. Psychiatric and Mental Health Congress

CNS Response, Inc. announced that the company will present top-line results from its multi-site clinical trial next week at the U.S. Psychiatric and Mental Health Congress. "Referenced-EEG (rEEG®) Efficacy Compared to Star*D for Patients with Depression Treatment Failure: First Look at Final Results," will be presented by Charles DeBattista, M.D. on Monday, November 2nd, at 3:45 to 6:45 p.m. The conference is being held at the Mandalay Bay South Convention Center in Las Vegas, NV.

29 Oct 2009

New study demonstrates that stem cell therapy may help prevent acute lung injury

Researchers at the University of Illinois at Chicago College of Medicine have shown that adult stem cells from bone marrow can prevent acute lung injury in a mouse model of the disease.

29 Oct 2009

No scientific proof that patients with Alzheimer's disease benefit from drugs containing the agent memantine

There is no scientific proof that patients with moderate or severe Alzheimer's disease benefit from drugs containing the agent memantine. This is the conclusion in the final report that the Institute for Quality and Efficiency in Health Care (IQWiG) published in September 2009.

29 Oct 2009

TNF therapy does not raise cancer risk in RA patients; overall cancer risk comparable to those not taking immunosuppressive drugs

A recent study by Swedish researchers found that rheumatoid arthritis (RA) patients did not experience an elevated cancer risk in the first 6 years after starting anti-tumor necrosis factor (TNF) therapy.

29 Oct 2009

New anti-cancer medications may help in managing cancerous conditions

Bold new strategies in the battle against cancer may turn forms of the disease that presently are incurable into manageable conditions that can be controlled for long periods of time, according to an article in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine.

29 Oct 2009

Statement regarding the need to eliminate waste and fraud in Medicare and Medicaid submitted

Mr. Chairman and Ranking Member, on behalf of the American Association for Homecare's more than 4,000 member locations serving Medicare beneficiaries in every state in the nation, we appreciate the opportunity to submit this statement to the Senate Committee on the Judiciary regarding the need to eliminate waste and fraud in Medicare and Medicaid.

29 Oct 2009

Crescent Healthcare to implement its Medical Management Solutions at Providence's Los Angeles area hospitals

Crescent Healthcare has signed a strategic partnership agreement with Providence Health & Services, California to implement its Medical Management Solutions (MMS) at three of Providence's Los Angeles area hospitals.

29 Oct 2009

Moores UCSD Cancer Center awarded $20 million for cancer research

Researchers led by Moores UCSD Cancer Center Director Dennis A. Carson, MD, professor of medicine, and Catriona Jamieson, MD, PhD, assistant professor of medicine and director of the Cancer Stem Cell Research Program at the Moores UCSD Cancer Center have been awarded $20 million over four years to develop novel drugs against leukemia stem cells.

28 Oct 2009

U.S. Department of Defense funds Rush University Medical Center for gastrointestinal microorganism research

The human body contains billions of microorganisms, and microbial cells found in the human gut are estimated to outnumber human cells by ten-to-one in healthy adults. However, little is known about the ways in which these minute life forms influence health and disease.

28 Oct 2009

NIH awards Excelimmune grant to develop treatment for Clostridium difficile infection

Excelimmune, Inc. (www.excelimmune.com) announced today that the National Institutes of Health (NIH) has awarded the company a Small Business Innovation Research (SBIR) grant to support research aimed at developing new treatments for Clostridium difficile (C. difficile) infection, employing Excelimmune’s expertise in developing novel antibody therapies for human disease.

28 Oct 2009

NCI awards UAMS Myeloma Institute $19.5M grant

The internationally known multiple myeloma program at the University of Arkansas for Medical Sciences (UAMS) will receive $19.5 million over five years to continue work that has already developed new treatments for this cancer of plasma cells, a type of white blood cell present in the bone marrow.

28 Oct 2009

MedX Health signs marketing agreement with MMB GmbH

MedX Health Corp., a global leader in developing drug free, non-invasive, low level laser and light therapy for tissue repair and pain relief, today announced that the company will be expanding its sales and marketing efforts with the new European master distributor MMB GmbH.

28 Oct 2009

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

According to new results from the WELCOME trial, exploratory data analyzing the impact of treatment with CIMZIA(®) (certolizumab pegol) - the only PEGylated anti-TNF (alpha) (Tumor Necrosis Factor alpha) - administered either every two weeks or every four weeks, showed that the majority of Crohn's disease patients in both dosing groups experienced no hospitalizations and surgical procedures during the course of the 26-week study.

28 Oct 2009

Third quarter 2009 financial results announced by DJO

DJO Incorporated (“DJO” or the “Company”), a global provider of medical device solutions for musculoskeletal health, vascular health and pain management, today announced financial results for its operating subsidiary, DJO Finance LLC (“DJOFL”), for the third quarter of 2009, ended September 26, 2009.

28 Oct 2009

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Nektar Therapeutics today announced that it has completed enrollment ahead of schedule in its Phase 2 clinical study of NKTR-102 in platinum-resistant ovarian cancer. NKTR-102 is Nektar's investigational proprietary compound currently being evaluated in Phase 2 clinical development in ovarian, breast and colorectal cancers.

28 Oct 2009

Global sales volumes of Levulan Kerastick exceed one million units

DUSA Pharmaceuticals, Inc.®, a specialty pharmaceutical company focused on dermatology, announced today that global sales volumes of the Levulan® Kerastick®, an integral part of the Levulan® Photodynamic Therapy (PDT) technology platform, surpassed one million units.

28 Oct 2009

New CCS guidelines and position papers for physicians and nurse practitioners

Several new guidelines and position papers offering the most up to date information to ensure that clinicians practice evidence-based medicine were released at the Canadian Cardiovascular Congress 2009 this week.

28 Oct 2009

Auxilium Pharmaceuticals reports increased net revenues of $42.1 million in third quarter 2009

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced financial results and operational highlights for the quarter ended September 30, 2009. For the third quarter of 2009, Auxilium reported net revenues of $42.1 million compared to net revenues of $32.6 million in the third quarter of 2008.

28 Oct 2009

Study of ‘real-life’ experiences of patients undergoing 5-ASA treatment for ulcerative colitis

InfoMedics, Inc., a company that engages patients and physicians to communicate better through the delivery of treatment feedback, has poster presentations at three industry conferences in October 2009. All of these studies provide a unique look at real-life patient feedback regarding experiences with medications for chronic conditions including ulcerative colitis (UC) and attention-deficit/hyperactivity disorder (ADHD) in adults and children.

28 Oct 2009

Interlace Medical receives 510K clearance to market MyoSure Hysteroscopic Tissue Removal System

Interlace Medical, Inc., today announced that it has received 510K clearance from the U. S. Food and Drug Administration (FDA) to market the MyoSure Hysteroscopic Tissue Removal System for the removal of submucosal fibroids and polyps.

28 Oct 2009

Therapy News and Research

CNS Response to present results from depression efficacy study at U.S. Psychiatric and Mental Health Congress

New study demonstrates that stem cell therapy may help prevent acute lung injury

No scientific proof that patients with Alzheimer's disease benefit from drugs containing the agent memantine

TNF therapy does not raise cancer risk in RA patients; overall cancer risk comparable to those not taking immunosuppressive drugs

New anti-cancer medications may help in managing cancerous conditions

Statement regarding the need to eliminate waste and fraud in Medicare and Medicaid submitted

Crescent Healthcare to implement its Medical Management Solutions at Providence's Los Angeles area hospitals

Moores UCSD Cancer Center awarded $20 million for cancer research

U.S. Department of Defense funds Rush University Medical Center for gastrointestinal microorganism research

NIH awards Excelimmune grant to develop treatment for Clostridium difficile infection

NCI awards UAMS Myeloma Institute $19.5M grant

MedX Health signs marketing agreement with MMB GmbH

New data from CIMZIA WELCOME trial to be presented at the ACG meeting

Third quarter 2009 financial results announced by DJO

Enrollment for Phase 2 clinical study of NKTR-102 completed ahead of schedule

Global sales volumes of Levulan Kerastick exceed one million units

New CCS guidelines and position papers for physicians and nurse practitioners

Auxilium Pharmaceuticals reports increased net revenues of $42.1 million in third quarter 2009

Study of ‘real-life’ experiences of patients undergoing 5-ASA treatment for ulcerative colitis

Interlace Medical receives 510K clearance to market MyoSure Hysteroscopic Tissue Removal System

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News